MEI Pharma (NASDAQ:MEIP) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of MEI Pharma (NASDAQ:MEIP) in a research note published on Sunday. The brokerage issued a buy rating on the stock.

MEI Pharma Trading Up 0.7 %

MEIP stock opened at $2.82 on Friday. The company has a market cap of $18.78 million, a P/E ratio of -0.40 and a beta of 0.83. MEI Pharma has a 52 week low of $2.61 and a 52 week high of $6.91. The company’s 50-day moving average price is $2.87 and its 200 day moving average price is $3.00.

MEI Pharma (NASDAQ:MEIP) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.20) EPS for the quarter. On average, equities research analysts expect that MEI Pharma will post -5.1 earnings per share for the current year.

Institutional Trading of MEI Pharma

A number of institutional investors have recently added to or reduced their stakes in MEIP. National Bank of Canada FI raised its position in MEI Pharma by 43.5% during the second quarter. National Bank of Canada FI now owns 33,000 shares of the company’s stock worth $94,000 after acquiring an additional 10,000 shares during the last quarter. Corsair Capital Management L.P. acquired a new position in MEI Pharma during the third quarter worth about $69,000. Finally, World Investment Advisors LLC acquired a new position in MEI Pharma during the third quarter worth about $71,000. Hedge funds and other institutional investors own 52.38% of the company’s stock.

About MEI Pharma

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.